The expression and clinical significance of miR-132 in gastric cancer patients

Diagnostic Pathology

Volumn 9, Issue 1, 2014, Pages

  Liu, Xiaowen ^a,b   Yu, Hongmei ^a,b   Cai, Hong ^a,b   Wang, Yanong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Biological markers; Gastric cancer; Prognosis

Indexed keywords

MICRORNA; MIRN132 MICRORNA, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897490151     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-9-57     Document Type: Article

References (39)

1. Shibata A, Parsonnet J. Stomach cancer. Cancer Epidemiology and Prevention 2006, 707-720. New York: Oxford University Press, Schottenfeld D, Fraumeni JF, 3.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R, Faloppi L, Cascinu S. Toward molecularly selected chemotherapy for advanced gastric cancer: stage of the art and future perspectives. Cancer Treat Rev 2009, 35(5):451-462. 10.1016/j.ctrv.2009.04.008, 19467788.
4. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett 2008, 266(2):99-115. 10.1016/j.canlet.2008.02.053, 18381231.
5. Hutvágner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002, 297(5589):2056-2060. 10.1126/science.1073827, 12154197.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866. 10.1038/nrc1997, 17060945.
7. Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'IncaIci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, DiFeo A. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 2014, 5:2977. 3896774, 24394555.
8. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H. MicroRNA-132 potentiates cholinergic anti-inflammatory signalling by targeting acetylcholinesterase. Immunity 2009, 31(6):965-973. 10.1016/j.immuni.2009.09.019, 20005135.
9. Mulik S, Xu J, Reddy PB, Mulik S, Xu J, Reddy PB, Rajasaqi NK, Gimenez F, Sharma S, Lu PY, Rouse BT. Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus. Am J Pathol 2012, 181(2):525-534. 10.1016/j.ajpath.2012.04.014, 3409434, 22659469.
10. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH. microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci USA 2010, 107(47):20382-20387. 10.1073/pnas.1015691107, 2996687, 21059906.
11. Zhang B, Lu L, Zhang X, Ye W, Wu J, Xi Q, Zhang X. Has-miR-132 regulates apoptosis in Non-small cell lung cancer independent of acetylcholinesterase. J Mol Neurosci 2013, [Epub ahead of print].
12. Yang J, Gao T, Tang J, Cai H, Lin L, Fu S. Loss of microRNA-132 predicts poor prognosis in patients with primary osteosarcoma. Mol Cell Biochem 2013, 381(1-2):9-15.
13. Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu F, Fan Y, Lang R, Fu L, Gu L, Qi L. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract 2013, 209(3):179-183. 10.1016/j.prp.2012.12.002, 23399321.
14. Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, Liu R, Wu Z. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal 2013, 25(5):1037-1043. 10.1016/j.cellsig.2013.01.019, 23376496.
15. Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agrò E, Levine AJ, Melino G, Bernardini S, Candi E. DNA methylation silences miR-132 in prostate cancer. Oncogene 2013, 32(1):127-134. 10.1038/onc.2012.14, 22310291.
16. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J, Shao C. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011, 32(8):1183-1189. 10.1093/carcin/bgr105, 21665894.
17. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 2003, 21:258-270. 10.1002/humu.10180, 12619111.
18. Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology 2002, 63:180-184. 10.1159/000063813, 12239454.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
20. Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y. The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One 2011, 6(12):e29670. 10.1371/journal.pone.0029670, 3247293, 22216342.
21. Song F, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X, Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. Clin Cancer Res 2014, 20(4):878-889. 10.1158/1078-0432.CCR-13-1844, 24352645.
22. Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T. c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS One 2013, 8(11):e79137. 10.1371/journal.pone.0079137, 3817069, 24223894.
23. Ito T, Yamada S, Tanaka C, Ito S, Murai T, Kobayashi D, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Kodera Y. Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer. Ann Surg Oncol 2014, 21(2):560-568. 10.1245/s10434-013-3246-5, 24046108.
24. Dong X, Wang G, Zhang G, Ni Z, Suo J, Cui J, Cui A, Yang Q, Xu Y, Li F. The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. Diagn Pathol 2013, 8:45. 10.1186/1746-1596-8-45, 3621381, 23510199.
25. Zhang G, Qu Y, Dang S, Yang Q, Shi B, Hou P. Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients. Diagn Pathol 2013, 8(1):173. 10.1186/1746-1596-8-173, 24144008.
26. Guan Z, Zhang J, Song S, Dai D. Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn Pathol 2013, 8(1):110. 10.1186/1746-1596-8-110, 3737241, 23819566.
27. Liu X, Xiong H, Li J, He Y, Yuan X. Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. Diagn Pathol 2013, 8:62. 10.1186/1746-1596-8-62, 3674969, 23587030.
28. Jin J, Jin T, Quan M, Piao Y, Lin Z. Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma. Diagn Pathol 2012, 7:135. 10.1186/1746-1596-7-135, 3502371, 23039327.
29. Nudelman AS, DiRocco DP, Lambert TJ, Garelick MG, Le J, Nathanson NM, Storm DR. Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo. Hippocampus 2010, 20(4):492-498. 2847008, 19557767.
30. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010, 16(8):909-914. 10.1038/nm.2186, 3094020, 20676106.
31. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ, Schmittgen TD. miR-132 and miR212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 2011, 406(4):518-523. 10.1016/j.bbrc.2011.02.065, 3069485, 21329664.
32. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH, Impey S. A cAMP-response element binding protein-induced microRNA regulates neuronal morphogenesis. Proc Natl Acad Sci USA 2005, 102(45):16426-16431. 10.1073/pnas.0508448102, 1283476, 16260724.
33. Zhang D, Ma QY, Hu HT, Zhang M. beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 2010, 10:19-29. 10.4161/cbt.10.1.11944, 20424515.
34. Jiang L, Chang J, Zhang Q, Sun L, Qiu X. MicroRNA has-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Invest 2013, 31(8):538-544. 10.3109/07357907.2013.820314, 24044511.
35. Zhang N, Wei X, Xu L. miR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett 2013, 587(15):2346-2351. 10.1016/j.febslet.2013.05.059, 23747308.
36. Wang B, Hsu SH, Wang X, Kutay H, Bid HK, Yu J, Ganju RK, Jacob ST, Yuneva M, Ghoshal K. Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2. Hepatology 2014, 59(2):555-566. 10.1002/hep.26712, 24038073.
37. Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, Lobie PE, Zhu T. c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting sprouty2. J Biol Chem 2013, 288(25):18121-18133. 10.1074/jbc.M113.478560, 23649631.
38. Parker NR, Correia N, Crossley B, Buckland ME, Howell VM, Wheeler HR. Correlation of MicroRNA 132 Up-regulation with an unfavorable clinical outcome in patients with primary glioblastoma multiforme treated with radiotherapy plus concomitant and adjuvant temozolomide chemotherapy. Transl Oncol 2013, 6(6):742-748. 3890709, 24466377.
39. Wang J, Xu G, Shen F, Kang Y. miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. Tumour Biol 2014, [Epub ahead of print].